Leerink Partnrs Has Strong Forecast for IPSC FY2024 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Century Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of ($0.09) for the year, up from their prior estimate of ($1.75). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share. Leerink Partnrs also issued estimates for Century Therapeutics’ Q4 2024 earnings at $0.93 EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.54) EPS and FY2028 earnings at ($1.32) EPS.

Several other analysts also recently commented on the stock. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a report on Wednesday, January 22nd. Piper Sandler lowered their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a report on Monday, December 30th. Finally, Chardan Capital lowered their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Century Therapeutics has an average rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Trading Up 2.8 %

Century Therapeutics stock opened at $0.77 on Monday. Century Therapeutics has a 1-year low of $0.68 and a 1-year high of $5.51. The firm has a market capitalization of $65.86 million, a price-to-earnings ratio of -0.42 and a beta of 1.73. The firm’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.35.

Institutional Trading of Century Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in Century Therapeutics during the third quarter worth about $27,000. Marshall Wace LLP purchased a new position in shares of Century Therapeutics in the fourth quarter worth about $36,000. Jane Street Group LLC increased its stake in shares of Century Therapeutics by 166.2% in the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Century Therapeutics in the fourth quarter worth about $53,000. Finally, Barclays PLC increased its stake in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after purchasing an additional 45,797 shares in the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.